Last updated: August 16, 2026

Application No. 18/686,480

FUSION PROTEIN OF INTERLEUKIN 2 AND APPLICATION THEREOF IN IBD

Non-Final OA

Filed

Feb 26, 2024

Priority

Aug 25, 2021 — CN 202110982310.8 +1 more

Examiner

HAMA, JOANNE

Art Unit

Tech Center

Assignee

BEIJING VDJBIO CO., LTD.

OA Round

1 (Non-Final)

This examiner grants 25% of cases after interview

— +38.8% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 259 resolved cases, 2023–2026

Examiner Intelligence

HAMA, JOANNE View full profile →

Grants only 25% of cases

Career Allowance Rate

65 granted / 259 resolved

-34.9% vs TC avg

Strong +39% interview lift

Without

With

+38.8%

Interview Lift

resolved cases with interview

Typical timeline

3y 8m

Avg Prosecution

62 currently pending

Career history

306

Total Applications

across all art units

Statute-Specific Performance

§101

6.9%

-33.1% vs TC avg

§103

39.2%

-0.8% vs TC avg

§102

15.9%

-24.1% vs TC avg

§112

24.8%

-15.2% vs TC avg

Black line = Tech Center average estimate • Based on career data from 259 resolved cases

Prosecution Timeline

Feb 26, 2024

Application Filed

Jul 31, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/243,129

Patent 12692322

KRAS SPECIFIC ANTIBODIES AND USES THEREOF

5y 3m to grant Granted Jul 28, 2026

17/273,212

Patent 12648929

COMPOSITIONS AND METHODS FOR PREVENTING AND/OR TREATING FILARIAL DISEASE

5y 3m to grant Granted Jun 09, 2026

17/631,797

Patent 12595300

ANTI-HUMAN P40 PROTEIN DOMAIN ANTIBODY AND USE THEREOF

4y 2m to grant Granted Apr 07, 2026

17/843,232

Patent 12559553

IL-31 MODULATORS FOR TREATING FXR-INDUCED PRURITUS

3y 8m to grant Granted Feb 24, 2026

17/808,379

Patent 12553897

USE OF CIRCULATING INTERLEUKIN-18 FOR PROGNOSTICATING AND TREATING RECURRENCE IN EARLY STAGE NON-SMALL CELL LUNG CANCER

3y 8m to grant Granted Feb 17, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

25%

Grant Probability

64%

With Interview (+38.8%)

3y 8m (~1y 2m remaining)

Median Time to Grant

Low

PTA Risk

Based on 259 resolved cases by this examiner. Grant probability derived from career allowance rate.